IGF2BP2 has been identified as a regulator of differentiation, and serves posttranscriptional regulation to participate in the differentiation of cancer and cancer stem cells [15], such as hepatocellular carcinoma [16], liposarcoma [17], glioblastoma [18], etc. Previous studies have demonstrated that IGF2BP2 was upregulated in thyroid cancer and strongly correlated with disease-free survival and clinical phenotypes of PTC [19,20]. This evidence concerns the gene IGF2BP2 and thyroid cancer.